| Ytd | -39.06% | |
| 1y | -67.28% |
| Open | 0.57 | Prev Close | 0.58 | Low | 0.57 | High | 0.61 | Mkt Cap | 162.68M |
| Vol | 6.99M | Avg Vol | 9.98M | EPS | -0.52 | P/E | N/A | Forward P/E | -5.41 |
| Beta | 1.47 | Short Ratio | 6.37 | Inst. Own | 30.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.64 | 200-d Avg | 0.91 | 1yr Est | 13.71 |
HUMA News
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% ch
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage b
Extension for Symvess (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended she
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr.,
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Admin
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Admin
NEW YORK and NEW ORLEANS, Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charle
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, includi
Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) a
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lo
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus E
Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expan
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.16) per share which missed the analyst conse
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperfor
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr.,
DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from i
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from i
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter
In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Bu
Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a
Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universal
The V012 clinical study is designed to demonstrate the efficacy and safety of the ATEV as a dialysis
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and ra
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Humacyte (NASDAQ:HUMA) with a B
Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Sm